New antibody-chemo combo offers hope for kids with aggressive nerve cancer
Disease control
Recruiting now
This study tests whether adding an antibody called hu14.18K322A to standard chemotherapy can better shrink or eliminate tumors in children and teens with high-risk neuroblastoma, a rare and aggressive nerve cancer. About 144 participants aged 18 months to under 18 years will rece…
Phase: PHASE2, PHASE3 • Sponsor: Renaissance Pharma Ltd. • Aim: Disease control
Last updated May 08, 2026 12:01 UTC